1. Home
  2. VIRC vs RNTX Comparison

VIRC vs RNTX Comparison

Compare VIRC & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Virco Manufacturing Corporation

VIRC

Virco Manufacturing Corporation

HOLD

Current Price

$6.53

Market Cap

95.5M

ML Signal

HOLD

RNTX

Rein Therapeutics Inc.

HOLD

Current Price

$0.96

Market Cap

80.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VIRC
RNTX
Founded
1950
2001
Country
United States
United States
Employees
N/A
10
Industry
Industrial Specialties
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
95.5M
80.7M
IPO Year
1995
N/A

Fundamental Metrics

Financial Performance
Metric
VIRC
RNTX
Price
$6.53
$0.96
Analyst Decision
Hold
Buy
Analyst Count
1
2
Target Price
$7.30
$10.00
AVG Volume (30 Days)
47.1K
475.0K
Earning Date
04-08-2026
05-15-2026
Dividend Yield
1.65%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$199,652,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$19.77
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.16
$0.89
52 Week High
$9.07
$2.18

Technical Indicators

Market Signals
Indicator
VIRC
RNTX
Relative Strength Index (RSI) 63.51 38.81
Support Level $5.99 N/A
Resistance Level $6.73 $1.33
Average True Range (ATR) 0.23 0.08
MACD 0.05 0.00
Stochastic Oscillator 92.38 24.28

Price Performance

Historical Comparison
VIRC
RNTX

About VIRC Virco Manufacturing Corporation

Virco Manufacturing Corp is engaged in designing, production and distributing quality furniture for the commercial and education markets. The company manufactures an assortment of products, including mobile tables, mobile storage equipment, desks, computer furniture, chairs, activity tables, folding chairs, and folding tables. Its primary furniture lines are constructed of tubular metal legs and frames, combined with wood and plastic tops, plastic seats and backs, upholstered seats and backs, and upholstered rigid polyethylene and polypropylene shells.

About RNTX Rein Therapeutics Inc.

Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. Its pipeline includes: LTI-03, a peptide, for placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling; LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment.

Share on Social Networks: